Search for a trial

A prospective *proof of concept study* to evaluate the potential efficacy of ustekinumab in patients with moderate to severe hidradenitis suppurativa (acne ectopica)

Primary objective: 1. To evaluate the effect of ustekinumab in patients with moderate to severe hidradenitis suppurativa (Hurley II-III), measured by disease specific score systmes: Sartorius/HS-LASI and PGA 2. To evaluate possible changes in scores…

A prospective study to determine the minimal biologic drug serum trough concentration required to maintain stable disease activity in patients with moderate to severe chronic plaque psoriasis.

To determine the minimal biologic drug serum trough concentration required to maintain stable disease activity in patientswith moderate to severe chronic plaque psoriasis.

An exploratory trial to assess naturalistic safety and efficacy outcomes in patients trasitioned to ustekinumab from previous methotrexate therapy

Primary Objective: The primary objective of this exploratory trial is to evaluate the comparative safety through Week 12 of two treatment transition strategies in patients with inadequate response to methotrexate: discontinuation of methotrexate…

Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.

To investigate whether the dose of biologics can be reduced in patients with psoriasis with stable disease: is dose reduction non-inferior to the current practice regarding clinical effectiveness? Secondary aims are: to investigate what influence…

Mechanism of action study of Ustekinumab treatment in psoriatic arthritis:
Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling

ObjectivePlease describe:• the specific goal to be reached by the study• the hypothesis to be answered by the studyThe overall aim of the study is to determine which downstream cellular and molecular pathways involved in PsA pathogenesis are…

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn*s Disease Patients Treated with Ustekinumab

A *treat to target* strategy has been advocated as an optimized management approach for various diseases, by which strictly defined treatment targets facilitate decision making in clinical practice. Key to the success of this treatment strategy is…

A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

This study has been transitioned to CTIS with ID 2023-507144-36-00 check the CTIS register for the current data. Primary:Evaluate PK and efficacy of ustekinumab and guselkumab in jPsA. Secondary:Evaluate safety of ustekinumab and guselkumab in…

A phase 3, multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn*s Disease who have failed anti-TNF therapy.

This study has been transitioned to CTIS with ID 2022-501645-70-00 check the CTIS register for the current data. Part 1:The objective is to compare the efficacy and safety of risankizumab versus ustekinumab over 48 weeks for the treatment of adult…